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In December 2015, an asylum seeker originating from 
Afghanistan was diagnosed with respiratory diph-
theria in Finland. He arrived in Finland from Sweden 
where he had already been clinically suspected and 
tested for diphtheria. Corynebacterium diphtheriae 
was confirmed in Sweden and shown to be genotypi-
cally and phenotypically toxigenic. The event high-
lights the importance of early case detection, rapid 
communication within the country and internationally 
as well as preparedness plans of diphtheria antitoxin 
availability. 
An asylum seeker from Afghanistan was diagnosed 
with respiratory diphtheria in Finland in December 
2015. He arrived in Finland from Sweden where he was 
already symptomatic with fever and respiratory symp-
toms and had been suspected for diphtheria. In this 
report we present details of this case investigation.
Case description
On 26 November 2015, an adolescent male originating 
from Afghanistan arrived in a transit accommodation 
centre designated for asylum seekers in Stockholm, 
Sweden. Prior to this, he had travelled from Afghanistan 
to Pakistan, then through Iran, Turkey, Greece, Serbia 
and Germany to Sweden (timeline of events presented 
in the Figure).
The case showed some symptoms (pharyngitis and 
fever) while in Germany (further details on duration 
of stay and locations not known) and upon arrival in 
Stockholm, he presented with intense pharyngitis, fever 
and general malaise and was rapidly escorted by the 
transit centre staff to a nearby emergency department 
where he stayed overnight. The preliminary diagno-
sis was tonsillitis positive for group A streptococcus 
(QuickVue Dipstick Strep A Test, TK Diagnostic, Oxford, 
United Kingdom). Oral penicillin was prescribed as 
treatment. As diphtheria was among the differential 
diagnoses, the attending physician also requested a 
specimen for throat culture. According to the patient, 
he had never received any vaccinations. The patient 
was discharged from the hospital and returned to the 
asylum accommodation centre. On the following day, 
27 November, he left the centre in Stockholm with two 
other asylum seekers and did not take the prescribed 
antibiotics along. Their travel destination was not clear 
at the time but according to the anecdotal evidence, 
Switzerland, Germany and Finland were mentioned.
On 29 November the asylum seeker arrived in Finland 
crossing the border in Northern Finland. He had trav-
elled from Stockholm to the north of Sweden by an 
overnight train from where he moved on to Finland by 
bus.
When arriving in Finland, he was still unwell and was 
immediately transferred to a regional central hospi-
tal where he was put in isolation as a precautionary 
measure. Streptococcal tonsillitis and mononucleo-
sis were initially suspected. Subsequently diphtheria 
was also considered and specimen for PCR amplifica-
tion (toxin gene) was taken on 30 November and for 
Corynebacterium diphtheria culture on 1 December. On 
2 December, the patient was transferred to the nearest 
university hospital for further treatment.
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While in hospital, the patient presented with malaise, 
sore throat and low-grade fever. Membranes in ton-
sils and soft palate were noticed. Carditis was evident 
with chest pain, ST-T wave changes in electrocardio-
graph and considerably elevated cardiac troponin I 
concentration (70 µg/l, norm: ≤0.04 µg/l). Treatment 
with intravenous cefuroxime and oral roxithromycin 
was introduced on 29 November and 20,000 IU diph-
theria antitoxin (DAT, Institute of Immunology, Croatia) 
was given on 2 and 4 December. On 11 December, the 
patient was assessed to be cured and discharged.
Laboratory findings in Sweden and Finland
On 4 December, the National Institute for Health and 
Welfare in Finland was alerted by a clinical laboratory 
the throat swab was positive for C. diphtheria toxin gene 
in the PCR. Isolation of the bacteria was attempted but 
was not successful. Prior penicillin therapy in Sweden, 
although incomplete, may have impeded a positive cul-
ture in this case.
In Sweden, on 1 December, the local county medical 
officer in Stockholm was alerted by the local clinical 
microbiological laboratory of a suspicion of diphtheria 
based on a positive Maldi-TOF finding of C. diphthe-
riae. The Public Health Agency of Sweden received the 
strain on the same day and informed on 2 December 
the local county medical officer of the presence of the 
diphtheria toxin gene (as analysed by PCR) in the iso-
late. The strain was Elek-positive confirming suspected 
toxin-production on 3 December and subsequently 
biochemical species determination confirmed the iso-
late to be C. diphtheriae and sub species non-gravis 
[personal communication, Karin Tegmark-Wisell, Public 
Health Agency of Sweden, December 2015].
On 7 December, Finland posted a message in the 
European Early Warning and Response System (EWRS) 
describing the event. Sweden replied the same day 
disclosing the details about patient’s travel itinerary, 
symptoms and laboratory findings before his arrival in 
Finland.
Specific and general public health measures 
in Sweden and Finland
The local public health authorities in Stockholm visited 
the transit accommodation centre on 3 and 4 December 
after the suspicion of diphtheria was notified (toxin 
positivity by PCR). The team examined the premises, 
obtained throat swabs and vaccinated nearly 20 ado-
lescents (mostly from Afghanistan) out of the ca 30 
persons who could have resided in the same room with 
the case patient. The other persons had already left 
the centre. None of the surveyed persons were ill and 
all cultures were negative.
In Finland, the patient was wearing a mask on the bus 
upon arrival (given by the police at the border) and 
was rapidly transferred to an isolation room after he 
crossed the border. Thus, the number of potentially 
exposed persons was limited. The contact details and 
Figure 1
Timeline of events for the diphtheria case, in an asylum seeker from Afghanistan arriving to Finland via Sweden, November 
to December 2015
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whereabouts of two travel companions from Stockholm 
were investigated but they could not be contacted.
The National Institute for Health and Welfare in Finland 
has recommended free of charge vaccination against 
diphtheria, tetanus (dT), polio (IPV), measles-mumps-
rubella (MMR) and influenza as a priority for all adult 
asylum seekers and refugees with an unknown or 
incomplete history of vaccination, or lack of protection 
gained through previous MMR infections. The children 
are offered the normal national immunisation pro-
gramme, modified and speeded up as appropriate. As 
an occupational health measure, the vaccination sta-
tus of all personnel working at the accommodation cen-
tres is checked and dT, MMR, influenza and hepatitis A 
vaccines are offered when necessary.
Background
Diphtheria is an acute bacterial disease primarily 
involving the mucous membrane of the upper respira-
tory tract, skin or seldom other mucous membranes 
[1,2]. The infection spreads from person to person 
through respiratory droplets, direct contact with res-
piratory secretions or from skin lesions. The incubation 
period is usually two to five days, sometimes up to 10 
days. The toxin-mediated disease caused by C. diph-
theria can be prevented by vaccination, which protects 
against the effects of exotoxin produced by the bacte-
ria [3].
This patient is the first diphtheria case diagnosed in 
Finland since 2001. Diphtheria is still endemic or epi-
demic in many regions of the world, including origin 
countries for current asylum seekers in Europe [3,4]. 
Discussion
Except for the present case, no cases of respiratory 
diphtheria were reported among asylum seekers and 
refugees since the current European refugee crisis 
started in 2015. Cases of cutaneous diphtheria were 
recently reported in refugees from Denmark, Germany 
and Sweden [5]. These events highlight the possibil-
ity of diphtheria among these vulnerable groups and 
underpins the need of national guidance regarding 
laboratory capacity for confirming diphtheria infec-
tions, raising awareness among clinicians, and early 
recognition and prompt implementation of prevention 
and control measures by the public health authorities. 
Since the exact timeline of the patient s´ travel itiner-
ary was unclear, the source of infection and whether 
it was acquired within or outside the European Union 
(EU) remains unknown. 
Our case further highlights that refugees arriving in 
the EU are likely not to be fully vaccinated against an 
array of vaccine-preventable diseases. They are conse-
quently at greater risk of communicable diseases such 
as diphtheria or measles. In Finland, the public health 
authorities recommend prompt vaccination of the newly 
arriving asylum seekers and refugees newcomers, ide-
ally within two weeks of arrival to the country. Due to 
logistics and resource constrains this target has not 
yet been achieved in most of the newly opened accom-
modation centres. As also shown in our case, another 
challenge to the immunisation activities is the mobility 
of refugees, not only cross-border but also within the 
country. The accommodation centre may change sev-
eral times during the asylum process, which addresses 
the need for reliable online registry with immunisation 
data available for all healthcare staff providing ser-
vices for the refugee population.
In general, refugees do not pose a threat to general 
population in Europe with respect to communicable 
diseases and they are themselves most vulnerable 
[6]. Since 1995, the vaccination coverage of Finnish 
children against diphtheria has been 94% to 99% [7]. 
However, there are no official estimates of the decen-
nial dT booster vaccination coverage among the adults 
and elderly persons. It is likely that at least a part of 
the adult population will be at risk for diphtheria and 
other vaccine preventable diseases. This emphasises 
the need for a vaccination policy that guarantees life-
long protection against significant infectious diseases 
threats.
The patient was treated with DAT which was available 
at the adjacent university hospital. The batch of DAT 
used had expired in March 2014 but was previously 
evaluated by the Finnish Medical Agency to be still 
safe and efficacious for use in emergency situation 
(personal communication, Pertti Sormunen, Director of 
Pharmaceutical Wholesale, National Institute for Health 
and Welfare, December 2015). The potency of the DAT 
was tested according to the European Pharmacopoeia 
monograph for Diphtheria Antitoxin (intradermal chal-
lenge in guinea pigs) by an authorised laboratory in 
February 2014. The diphtheria potency was still more 
than three times over the minimum level of 1,000 IU/
ml. No abnormal toxicity was detected.
The rapid administration of DAT is crucial for a suc-
cessful treatment effect [3]. However, a large number 
of EU Member States do not have stockpiles and many 
countries have difficulties in having rapid access to 
DAT, a problem highlighted in a recent case of diphthe-
ria in Spain [8]. Many countries ceased manufacturing 
DAT following the significant decline in incidence of 
the diphtheria after the mass vaccination campaigns 
in Europe [4]. The lack of DAT availability in the EU is 
worrying and needs urgent attention in the light of this 
event. Possibilities for joint procurement of DAT in the 
EU/European Economic Area (EEA) should be assessed 
as suggested by the European Centre for Disease 
Prevention and Control (ECDC) [8].
Prompt communication between clinicians, microbiol-
ogy laboratories and public health authorities is cru-
cial in the effective public health response. The patient 
was found PCR-positive for toxin gene on 2 December 
in Sweden (but yet not confirmed by culture) two 
days before the clinical laboratory in Finland alerted 
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the national public health institute about the positive 
PCR finding for the toxin gene. Swedish authorities 
were not fully aware of the travel route and thus not 
able to directly alert Finnish authorities before arrival 
in Finland. However, due to the apparent problems in 
DAT availability in the EU and the importance of rapid 
public health measures for treating and controlling 
diphtheria, we propose that any suspected or probable 
case among highly mobile migrant populations, is com-
municated through the EWRS as early as possible.
*Authors’ correction
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